Compound—827

A compound of formula (I)

• in which:
• A is a cyclohexane ring;
• R is hydrogen;
• R1 and R2 together with the nitrogen atom to which they are attached form a 5- to 7-membered monocyclic saturated or partially unsaturated heterocyclic ring, which ring shares at least one atom with a second monocyclic saturated, partially unsaturated or unsaturated ring so as to form a bicyclic ring system;
• which bicyclic ring system shares at least one atom with a third saturated, partially unsaturated or unsaturated ring so as to form a tricyclic ring system comprising up to 19 ring atoms,
• and wherein the tricyclic ring system optionally comprise up to five heteroatoms each independently selected from O, S or N atoms, and is optionally substituted by up to three substituents each independently selected from phenyl, benzyl, naphthyl, C1-6 alkyl, C2-6alkenyl, C2-6alkynyl, cyano, halogen, COOR3, COR3, NO2, OR3, CONR4R5, NR4R5, C1-2alkanesulfonyl-, monocyclic heteroaryl comprising up to 7 ring atoms, and bicyclic heteroaryl comprising up to 12 carbon atoms,
• and the tricyclic ring system is optionally substituted on adjacent carbon atoms by a group —O—C(R8)2—O—, wherein each R8 is hydrogen or a halogen atom, so as to form a 1,3-dioxolo group,
• and wherein
• (i) phenyl, naphthyl, C1-6 alkyl, C2-6alkenyl, C2-6alkynyl and benzyl are optionally further substituted by up to three substituents each independently selected from halogen, NR4R5, SO2R3, CONR4R5, cyano, OR3, SO2NR4R5, NSO2R3, NR4COR5, and C1-6 alkyl itself optionally substituted with up to three substituents independently selected from halogen, cyano, SO2R3, NR4R5, OR3, SO2NR4R5, NSO2R3, NR4COR5 and CONR4R5,
• and
• (ii) monocyclic or bicyclic heteroaryl are optionally further substituted by up to three substituents each independently selected from halogen, NR4R5, SO2NR4R5, NSO2R3, NR4COR5, CONR4R5, SO2R3, cyano, OR3, and phenyl itself optionally substituted with up to three halogen groups, SO2R3, or C1-6 alkyl itself optionally substituted with up to three substituents independently selected from halogen, cyano, SO2R3, SO2NR4R5, NSO2R3, NR4COR5, NR4R5, OR3, C3-7-carbocyclyl and CONR4R5;
• R3 is selected from hydrogen, C1-6 alkyl, C3-7carbocyclyl, phenyl, monocyclic heteroaryl, a 4-7 membered monocyclic saturated heterocyclic ring comprising up to three heteroatoms each independently selected from O, S or N atoms, and wherein C1-6 alkyl and phenyl and monocyclic heteroaryl can each be optionally substituted by up to three groups independently selected from halogen, cyano, CONR4R5, NR4R5, SO2NR4R5, NSO2R3 and SO2R3;
• R4 and R5 are independently hydrogen, C1-6 alkyl, COR3, monocyclic heteroaryl comprising up to 7 ring atoms or bicyclic heteroaryl comprising up to 12 ring atoms or together with the nitrogen to which they are attached form a 5- to 7-membered monocyclic saturated heterocyclic ring optionally comprising up to three additional heteroatoms each independently selected from O, S or N atoms and optionally substituted by C1-6 alkyl optionally substituted by NR6R7;
• R6 and R7 are independently hydrogen, C1-6 alkyl, or together with the nitrogen to which they are attached form a 5- to 7-membered monocyclic saturated heterocyclic ring optionally comprising up to three additional heteroatoms each independently selected from O, S or N atoms;
• or a pharmaceutically acceptable salt thereof.